Abstract:Background: Emerging HIV drug resistance caused by increased usage of antiretroviral drugs (ARV) could jeopardize the success of standardized HIV management protocols in resource-limited settings. Objective: We aimed to characterize pretreatment HIV drug resistance (PDR) among HIV-positive individuals and risk factors in China in 2022. Methods: This cross-sectional study was conducted using 2-stage systematic sampling according to the World Health Organization's surveillance guidelines in 8 provincial-level administrative divisions in 2022. Demographic information and plasma samples were obtained from study participants. PDR was analyzed using the Stanford HIV drug resistance database, and the Tamura-Nei 93 model in HIV-TRACE was used to calculate pairwise matches with a genetic distance of 0.01 substitutions per site. Logistic regression was used to identify and estimate factors associated with PDR. Results: PDR testing was conducted on 2568 participants in 2022. Of the participants, 34.8% (n=893) were aged 30-49 years, 81.4% (n=2091) were male, and 3.2% (n=81) had prior ARV exposure. The prevalence of PDR to protease and reverse transcriptase regions, nonnucleoside reverse transcriptase inhibitors, nucleoside reverse transcriptase inhibitors, and protease inhibitors were 7.4% (n=190), 6.3% (n=163), 1.2% (n=32), and 0.2% (n=5), respectively. Yunnan, Jilin, and Zhejiang had much higher PDR incidence than did Sichuan. The prevalence of nonnucleoside reverse transcriptase inhibitor-related drug resistance was 6.1% (n=157) for efavirenz and 6.3% (n=163) for nevirapine. Multivariable logistic regression models indicated that participants who had prior ARV exposure (odds ratio [OR] 7.45, 95% CI 4.50-12.34) and the CRF55_01B HIV subtype (OR 2.61, 95% CI 1.41-4.83) were significantly associated with PDR. Among 618 (24.2%) sequences (nodes) associated with 253 molecular transmission clusters (size range 2-13), drug resistance mutation sites included K103, E138, V179, P225, V106, V108, L210, T215, P225, K238, and A98. Conclusions: The overall prevalence of PDR in China in 2022 was modest. Targeted genotypic PDR testing and medication compliance interventions must be urgently expanded to address PDR among newly diagnosed people living with HIV in China.

[The Study of an In-House Method for Drug Resistance Genotyping Testing on HIV-1 Strains Prevailing in China].

Evaluation of an In-House Hiv-1 Drug Resistance Genotypic Testing for Using Dried Blood Spot Specimens in China

Genetic Diversity of Hiv-1 and Transmitted Drug Resistance among Newly Diagnosed Individuals with Hiv Infection in Hangzhou, China

Incidence And Associated Factors Of Hiv Drug Resistance In Chinese Hiv-Infected Patients Receiving Antiretroviral Treatment

[Survey of HIV Drug Resistance Threshold in Zhejiang Province from 2009 to 2011].

Hiv Drug Resistance And Its Impact On Antiretroviral Therapy In Chinese Hiv-Infected Patients

The prevalence of transmitted antiretroviral drug resistance in treatment-naive HIV-infected individuals in China.

[Prevalence of Drug Resistance Mutations among Antiretroviral Drug-Naive HIV-1-infected Patients in China].

Full-Spectrum Surveillance of Pre-Treatment HIV Drug Resistance in Southeastern China

HIV drug resistance: analysis of viral genotypes and mutation loci in people living with HIV in Chongqing, China (2016-2023)

Surveillance of transmitted HIV type 1 drug resistance in newly diagnosed hiv type 1-infected patients in Shandong Province, China.

The genotype distribution, infection stage and drug resistance mutation profile of human immunodeficiency virus-1 among the infected blood donors from five Chinese blood centers, 2014–2017

HIV drug resistance among newly-diagnosed HIV-infected patients in Taizhou prefecture of Zhejiang Province

Molecular Transmission Network and Drug Resistance in Treatment-Naive HIV-1-Infected Patients in the Liangshan District, China

[Primary Drug Resistance of Human Immunodeficiency Virus (hiv)among the Treatment-Naive Individuals with HIV in China: a Meta-Analysis].

Prevalence of HIV-1 Drug Resistance among HAART-Virological Failure Patients Between 2011 and 2012 in Hebei, China.

Study of HIV-1 Drug Resistance in Patients Receiving Free Antiretroviral Therapy in China

Using Molecular Transmission Networks to Reveal the Epidemic of Pretreatment HIV-1 Drug Resistance in Guangxi, China

The Prevalence of Drug Resistance Mutations among Treatment-Naive Hiv-Infected Individuals in Beijing, China

Genotypes and Transmitted Drug Resistance among Treatment-Naive HIV-1-Infected Patients in a Northwestern Province, China: Trends from 2003 to 2013

Pretreatment HIV Drug Resistance and the Molecular Transmission Network Among HIV-Positive Individuals in China in 2022: Multicenter Observational Study